Details
Category: Volume 06 Issue 12 December 2018
Hits: 1468

Title: Lymph Node Dissection in Interval Debulking Surgery: Two Years Analysis

Authors: Debabrata Barmon, Dimpy Begum, A.C. Kataki, Todak Taba, Helen Kamei

 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.55

Abstract

Background and Objectives: ovarian cancer comprise 4% of all women cancer and 34% amongst gynaecological tract cancer. Lymphatic dissemination to the pelvic and para-aortic lymph node seen in usually advanced stage disease. Retroperitoneal lymph node involvement occur in approximately 50% to 80% of women with advanced ovarian cancer. The role of routine lymph node dissection is still not clear in interval debulking surgery.

Materials and Methods: all ovarian histologically proven adenocarcinoma cases receiving neoadjuvant chemotherapy and undergoing debulking surgery with or without routine lymphadenectomy operated during the period 2013-14 were included in the study and divided into control and cases arm. Outcome measurement were done in relation to progression-free survival (PFS) to detection of progression of disease or death with number of hospital stay peri-operative and postoperative complication.

Results: Lymph node dissecting group of patients showed longer intraoperative period with significant amount of blood loss with longer hospital stay without any benefit over overall and progression free survival.

Conclusion: a routine pelvic lymphadenectomy for stage III and IV ovarian cancer during interval debulking has no advantage over recurrence and progression or overall survival and is associated with higher morbidity.

Keywords: ovarian carcinoma, pelvic lymphnodadenectomy, paraaortic lymphadenectomy

References

  1. Walsh P, Cooper N. Ovary. In: Quinn M, Wood H, Cooper N, Rowan S editor(s). Cancer Atlas of the United Kingdom and Ireland 1991-2000. Newport: Office for National Statistics, 2005:193-201.
  2. Web of Science Times Cited: 63. GLOBOCAN2010Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. Cancer Incidence and Mortality Worldwide. GLOBOCAN 2008. IARC Cancer Base No 10 [Internet] 2010; Vol. International Agency for Research on Cancer, issue..
  3. Hannibal C, Cortes R, Engholm G, Kjaer S. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five year relative survival in the period 1978-2002. Acta Obstetricia et Gynecologica Scandinavica 2008; 87(12):1353-60.
  4. American Cancer Society. Survival rates for ovarian cancer, by stage.http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates 21 March 2013.
  5. Heintz A, Odicino F, Maisonneuve P, Quinn M, Benedet J, Creasman W, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynaecology and Obstetrics 2006 Nov;95(1):161-92.PubMed
  6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T. Cancer statistics. CA: A Cancer Journal for Clinicians 2008;58:71-96.PubMed
  7. Burghardt,F. Giardi M.Lahousen,et al pattern of pelvic and paraaortic lymph node involvement in ovarian cancer,cancer,” Gynaecologic Oncology vol40 no.2 1991 PP103-106.doi10.1016/0090-8258(91)90099-Q
  8. Bhoola S, Hoskins W. Diagnosis and management of epithelial ovarian cancer. Obstetrics and Gynecology 2006;107(6):1399-410.
  9. Du Bois A.and Pfisterer, J.(2005). Future option s for first-line therapy of advanced ovarian cancer.int J Gynacol 15(suppl. 1):42-50
  10. Piganata,S, Scambia, G. Ferrandina, G. Savarese, A., Sorio, R, Breda, E. Et al.(2011) carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer :the MITO-2 randomized phase-III trial. J Clin oncol29:3628-35.
  11. .National Institute for Health and Clinical Excellence. Guidelines Manual. www.nice.org.uk/guidelinesmanual 2011
  12. Winter-Roach B, Kitchener H, Lawrie T. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD004706.pub4]CrossRef | PubMed | Web of Science®
  13. du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J, et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733–1739. [PubMed]
  14. Van Der Burg M.,Van Lent, M.,Buys, M.,Colombo, N, Favalli,G.ET AL(1995). The effect of debulking surgery after induction chemotherapy on the progreesion in advanced epithelial ovarian cancer. Gynaecological cancer cooperative group of European organization for research and treatment of cancer. N . Engl J Med 332:629-634.
  15. Rose, P, Nerenstone, S, brady ,M, Clark-Pearson ,D. olt, G. Rubin, S, et al 2004.secondary advanced cytoreduction for advanced ovarian carcinoma. N Eng J Med 351:2489-2497.
  16. Fagotti A, De Iaco P , Fanfani F, Vizzielli G, Perelli F, Pozzati F, et al. Systematic pelvic and paraaortic lymphadenectomy in advanced ovarian cancer at the time f interval debulking surgery: a double  institution  case –control study. Ann surg oncol.2012; 19(11):3522-7
  17. Iwase H, Takada T, Iitsuka C, Nomura H. Clinical significance of systematic  retroperitoneal  lymphadenectomy during interval debulking surgery in advanced ovarian   Gynaecol oncol.2015;26(4):303-10
  18. Schwartz L, Schort –Sanyan S, Brigand C, Baldauf JJ, Wattiez A, Akladios C. Impact of pelvic and paraaortic lymphadenectomy in advanced ovarian cancer after neoadjuvant chemotherapy. Anticancer res.2015:35(10):5503-9

Corresponding Author

Dimpy Begum

Fellow Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.